CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Highlights Charles River Laboratories International, Inc. Berne S.E.

Stocks

RV6

US1598641074

Biotechnology & Medical Research

End-of-day quote Berne S.E. Other stock markets 2026-08-05			5-day change	1st Jan Change
211.14 ^CHF	+12.48%		+8.04%	-

08-05	Top Midday Gainers	MT
08-05	Charles River Laboratories International, Inc., Q2 2026 Earnings Call, Aug 05, 2026

Highlights

08-05	Top Midday Gainers	MT
08-05	Charles River Laboratories International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 27, 2026	CI
08-05	Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Fall; Lifts 2026 Guidance	MT
08-05	Charles River Laboratories International, Inc. Updates Earnings Guidance for 2026	CI
08-05	(CRL) Charles River Laboratories Expects 2026 Adjusted EPS Range $11.15 - $11.45, vs. FactSet Est of $11.11	MT
08-05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Revenue $1.00B, vs. FactSet Est of $977.2M	MT
08-05	Earnings Flash (CRL) Charles River Laboratories Posts Fiscal Q2 Adjusted EPS $3.02, vs. FactSet Est of $2.74	MT
08-05	Charles River lifts profit forecast on improving biotech demand	RE
07-13	Charles River Laboratories to Provide Cell Sequencing Services to Arovella Therapeutics	MT
07-13	Charles River Provides Ngs Services to Arovella Therapeutics, Accelerating Progress Toward Alternative Cancer Treatment Approaches	CI
05-13	Charles River Laboratories, Medipost Sign MoU on GMP-Compliant Testing	MT
05-11	Charles River Laboratories International, Inc. Approves Ratification of PricewaterhouseCoopers LLP as Independent Auditors	CI
05-11	Charles River Laboratories International, Inc. Accelerates Digital Pathology with Ai-Powered End-To-End Workflow	CI
05-08	Charles River Laboratories International, Inc. Seeks M&A Opportunities	CI
05-07	Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on November 5, 2025.	CI
05-07	Charles River Laboratories International, Inc. Reports Earnings Results for the First Quarter Ended March 28, 2026	CI
05-07	Charles River Laboratories Q1 Adjusted Earnings Decline, Revenue Rises; Maintains 2026 Earnings Guidance	MT
05-07	(CRL) Charles River Laboratories International Expects 2026 Non-GAAP EPS Range $10.80 - $11.30, vs. FactSet Est of $11.08	MT
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Posts Q1 Adjusted EPS $2.06 per Share, vs. FactSet Est of $1.94	MT
05-07	Charles River beats quarterly estimates on steady demand for drug development services	RE
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M	MT
05-07	Earnings Flash (CRL) Charles River Laboratories International, Inc. Reports Q1 Revenue $995.8M, vs. FactSet Est of $977.5M	MT
05-07	Charles River Laboratories International, Inc. Reports Consolidated Impairment Charges Results for the Quarter Ended March 28, 2026	CI
05-07	Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026	CI
05-05	GI Manager L.P. completed the acquisition of Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc..	CI